COX-2 inhibitors and cardiovascular risk

Area of Science:

• Cardiovascular Pharmacology
• Inflammation and Immunology

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) selective for cyclooxygenase-2 (COX-2) are associated with increased cardiovascular risk.
• COX-2 inhibitors (coxibs) selectively inhibit vascular prostacyclin synthesis, impacting cardiovascular homeostasis.
• Prostacyclin plays a crucial role in regulating platelet activation and vascular tone.

Purpose of the Study:

• To review the current understanding of coxibs and their cardiovascular risks.
• To explore recent mechanistic insights into how COX-2 inhibition contributes to cardiovascular events.
• To elucidate the roles of prostacyclin and prostaglandin E2 in cardiovascular homeostasis.

Main Methods:

• Analysis of placebo-controlled trials of selective COX-2 inhibitors.
• Utilizing novel mouse models for selective COX-2 inhibition.
• Employing models with disrupted microsomal prostaglandin E synthase-1.

Main Results:

• Selective COX-2 inhibition impairs prostacyclin synthesis, potentially leading to thrombosis and hypertension.
• The disruption of prostacyclin's regulatory functions contributes to cardiovascular risk.
• Novel mouse models provide insights into the specific roles of prostacyclin and prostaglandin E2.

Conclusions:

• COX-2 inhibition by coxibs is mechanistically linked to increased cardiovascular risk.
• Understanding the balance between prostacyclin and thromboxane is critical for cardiovascular health.
• Further research into COX-2 pathways is essential for developing safer anti-inflammatory therapies.